Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease

NCT04173273 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04173273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04173273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Terminated
Start date
January 6, 2020
Completion date
June 9, 2025
Enrollment
379 (actual)
Sites
510

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease